TG Therapeutics, Inc. TGTX
64.88 USD -1.24 (-1.88%)
Regular-session close
66.02 +1.14 +1.75%
After hours · Nov 19, 4:43 PM ET
64.62 Day range 67.19
26.76 52-week range 68.03
- YTD
- +117.65%
- 1 year
- +113.91%
News
businesswire.com TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™ NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 5 on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology,…
zacks.com 3 Stocks Rallying After Strong Q3 Earnings and Raised Guidance The Q3 earnings season has delivered several big winners, with Hasbro (HAS), IDEXX Laboratories (IDXX), and TG Therapeutics (TGTX) all posting strong results that have helped drive relative strength…
defenseworld.net 110,365 TG Therapeutics, Inc. $TGTX Shares Acquired by Fifth Third Bancorp Fifth Third Bancorp raised its position in TG Therapeutics, Inc. (NASDAQ: TGTX) by 181.1% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities…
fool.com TG Therapeutics: 3 Key Takeaways for Long-Term Investors TG Therapeutics raised full-year 2026 global revenue guidance to $1 billion. Subcutaneous BRIUMVI could more than double peak sales opportunity.
defenseworld.net TG Therapeutics, Inc. $TGTX Shares Newly Acquired by Ashton Thomas Private Wealth LLC Ashton Thomas Private Wealth LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ: TGTX) during the third quarter, according to the company in its most recent filing with the Securities and…
zacks.com TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up TG Therapeutics beats Q3 earnings and revenue estimates as Briumvi demand accelerates, shares rise 5.9%, and 2026 revenue guidance climbs to $1 billion.
zacks.com 4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.benzinga.com Evercore ISI Group Maintains Outperform on TG Therapeutics, Lowers Price Target to $71 Evercore ISI Group analyst Michael DiFiore maintains TG Therapeutics (NASDAQ:TGTX) with a Outperform and lowers the price target from $73 to $71.
defenseworld.net Calamos Advisors LLC Acquires New Stake in TG Therapeutics, Inc. $TGTX Calamos Advisors LLC bought a new position in TG Therapeutics, Inc. (NASDAQ: TGTX) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The…
seekingalpha.com TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call Transcript TG Therapeutics, Inc. ( TGTX ) Q3 2026 Earnings Call November 9, 2026 8:30 AM EST Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO &…
marketbeat.com What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call TG Therapeutics NASDAQ: TGTX raised its 2026 revenue outlook after third-quarter sales of its multiple sclerosis treatment BRIUMVI climbed 52% in the United States, and executives said they expect a…
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
zacks.com TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
zacks.com TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates TG Therapeutics (TGTX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $2.43 per share a year ago.
benzinga.com TG Therapeutics Q3 2026 Earnings Call Transcript TG Therapeutics (NASDAQ:TGTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com TG Therapeutics Raises FY2026 Sales Guidance from $950.000M to $1.000B vs $960.306M Est TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $950.000 million to $1.000 billion vs $960.306 million estimate.
benzinga.com TG Therapeutics Q3 EPS $0.35 Beats $0.34 Estimate, Sales $259.936M Beat $245.475M Estimate TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.34 by 2.94 percent. This is a 85.6 percent decrease over earnings of $2.43…
businesswire.com TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2026, along with recent…
seekingalpha.com Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep Correction I build my biotech investments using technical analysis, focusing on price action and volume, not traditional fundamentals. I target small-cap biotechs advancing past Phase 2, especially those…
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
zacks.com 4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
businesswire.com TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 9, 2026, at 8:30 AM ET to discuss results for the…
zacks.com GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
zacks.com TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
gurufocus.com TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an invesbenzinga.com TG Therapeutics' Initial Data From Its Phase 1 Trial Of Azercabtagene Zapreleucel In Patients With Progressive Multiple Sclerosis Demonstrates 89% Of Evaluable Participants Had Stable Or Improved Disability Scores At Day 90 TG Therapeutics, Inc. (NASDAQ:TGTX), today announced initial results from the Company’s Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed…
businesswire.com TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an…
